Dyax (DYAX), Eclipse Therapeutics Agree to Oncology Antibody License
Tweet
Share
E-mailGet Alerts DYAX Hot Sheet
Join SI Premium – FREE
Dyax Corp. (NASDAQ: DYAX) and Eclipse Therapeutics, Inc., a privately held oncology company, announced today that Dyax has granted Eclipse an exclusive worldwide license for the development and commercialization of preclinical fully-human antibodies discovered using Dyax’s gold-standard phage display technology for use in oncology indications. In exchange, Dyax will receive an initial license fee, payments upon the achievement of clinical development and sales milestones, and royalties on worldwide net sales resulting from commercialized products.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
- BIGG Digital Assets to rename as Surge Digital, consolidate shares
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
